AzTrials
AzTrials

Tobacco UseNCT07746492

Just-in-Time Support for Smoking, Vaping, and Eating Urges During High-Stress Moments Among Gender and Sexual Minority Adults in Dhaka

A study testing Just-in-Time Adaptive Support Message in people with Tobacco Use and Electronic Cigarette Use, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

Gender and sexual minority adults in Bangladesh experience high levels of stigma-related stress. Acute stress can trigger strong, affect-driven urges to smoke, vape, or engage in stress-attributed eating. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Just-in-Time Adaptive Support Message
Could I receive a placebo?
No, everyone receives an active treatment
How many people
115 participants
Where
1 siteBangladesh
Study dates
1 Sep 2026to 6 Feb 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18 years or older
  • Self-identifies as a gender and/or sexual minority person
  • Resides in Dhaka at enrolment and expects to remain in Dhaka throughout the 24-day assessment period
  • Reports at least one qualifying behaviour on average at least 3 days per week during the past month: (a) smoking or vaping, or (b) eating primarily in response to stress, anxiety, or emotional distress
  • Owns a personal Android or iOS smartphone compatible with the study platform that is used solely by the participant and is not shared with others
  • Able to read, understand, and respond to simple Bangla text
Show all 9Show fewer
  • Able to operate the study app independently after a structured onboarding session
  • Willing to complete five scheduled app-based momentary assessments per day for 24 days and additional brief follow-up assessments after randomized decision points
  • Provides written informed consent

Who cannot join

  • Currently participating in another behavioural or pharmacological intervention study targeting smoking, vaping, or eating behaviour
  • Has a severe or unstable psychiatric condition that, based on screening and review by the study clinician, would make participation in the repeated daily assessment protocol unsafe
  • Is unable to operate the study app independently after structured onboarding

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Bangladesh1 site
  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

    Dhaka

    Pritom K. Das, +8802222277144, pritom.das@icddrb.org

Other trials in Bangladesh

About this study

Official title: A Digital Real-Time Support for Stress-Induced Smoking and Unhealthy Eating Among Gender and Sexual Minorities in Dhaka

Gender and sexual minority adults in Bangladesh experience high levels of stigma-related stress. Acute stress can trigger strong, affect-driven urges to smoke, vape, or engage in stress-attributed eating. These urges can rise and fall within minutes to hours, operating outside the reach of conventional clinic-based interventions delivered days or weeks later.

This pilot micro-randomized trial (MRT) evaluates whether delivering a brief, culturally adapted support message via smartphone during moments of high self-reported stress reduces the intensity of the urge for the participant's pre-specified target behaviour, relative to no message. Over a 24-day period, 115 participants will be scheduled for up to 5 ecological momentary assessments (EMA) per day. Whenever a participant reports an acute stress level of 5 or higher (0 to 10 scale) and satisfies pre-specified privacy, safety, behavioural, and spacing criteria, the app randomizes with probability 0.5 to deliver either a brief support message or no message. By contributing multiple randomized decision points over time, each participant serves as their own micro-control.

Read more

The primary outcome is the intensity of the urge for the participant's pre-specified target behaviour, measured 45 to 60 minutes after randomization. An exploratory urge assessment is also collected 10 minutes after randomization; comparing the two time points will help establish whether the support message's effect is immediate, delayed, or both, and will inform the choice of follow-up window for a future, fully powered trial. Prior to trial launch, all EMA items, message content, notification logic, and digital safety protocols will be developed and tested with community members, reviewed by a Community Advisory Board, and locked.

As a pilot optimization trial, its objectives are to estimate the short-term causal effect of the prompt, to identify the contexts in which that effect is larger or smaller, and to establish whether momentary assessment and just-in-time intervention research can be delivered safely, privately, and acceptably in this high-stigma setting. The study does not evaluate long-term behavioural maintenance and does not claim to address the underlying structural stigma and discrimination that produce minority stress.

Read the detailed description

Registered Study and Formative Phase: The registered interventional study is a micro-randomized trial (MRT) involving 115 participants over a 24-day assessment period. It is preceded by a formative cultural adaptation and technical refinement phase conducted to develop, optimize, and lock the momentary assessment items, support message library, notification wording, and digital safety features. This preliminary phase comprises cognitive walkthroughs and think-aloud interviews with approximately 10 community members, a short structured momentary assessment run to characterize the naturalistic distribution of momentary stress ratings, and a technology validation period. The formative phase involves no randomization and no assignment to any intervention. It is not part of the registered interventional cohort, is not included in the registered enrollment figure, and does not determine the study start date.

Micro-Randomization Framework: Randomization occurs repeatedly within each participant rather than once between participants. Each participant is randomized at every decision point during the 24-day period that satisfies all predefined eligibility criteria, thereby contributing both intervention and control observations over time. The primary unit of randomization and proximal observation is the eligible decision point; repeated observations are nested within participants.

Decision Point Definition: Randomization occurs at available high-stress decision points, defined as a completed momentary assessment at which all five of the following conditions are satisfied simultaneously: the assessment is completed within the allowed 30-minute response window; the participant reports a current stress level of 5 or higher on a 0 to 10 scale; the participant confirms that it is currently safe and private enough to receive a message; the participant has not already reported performing their designated primary target behavior since the preceding completed assessment; and no randomization has occurred in the preceding 90 minutes. Moments that fail any criterion are logged by the platform for system audit and feasibility monitoring but are not randomized.

Randomization Procedure: At each available decision point, the digital platform randomizes prompt assignment independently, with a fixed probability of p = 0.50, to either delivery of a supportive coping prompt or no prompt (active assessment control). The randomization outcome and timestamp are securely logged.

Assessment Schedule and Conflict Resolution: Participants receive five scheduled baseline momentary assessments per day, delivered at randomized times within five pre-specified daily time blocks, with one assessment per block across the 24-day period. Following every randomization, in both the prompt and no-prompt conditions, participants complete a brief micro-check assessment at 10 minutes, with a 5-minute response window, and a main proximal follow-up assessment at 45 minutes, with a 15-minute response window. To prevent assessment overload and survey collision, if a regularly scheduled baseline assessment falls within 60 minutes after a randomization, that scheduled assessment is automatically suppressed by the platform and recorded as protocol-suppressed rather than missing.

Target Behaviour and Multi-Behavioral Logic: Participants who qualify on both smoking/vaping and stress-attributed eating designate a single primary target behavior at baseline. This designation is locked before the assessment period begins and remains fixed throughout the study to maintain primary outcome integrity. Urge intensity for both behaviors is measured at every momentary assessment to allow descriptive, exploratory characterization of urge patterns across behaviors, consistent with the pre-specified exploratory outcome measures; however, only the locked target behavior provides the primary confirmatory outcome. Urge scores for the two behaviors are analyzed independently and are never averaged or combined.

Sample Size and Power Assumptions: The target enrolment is 115 participants. Under the planning assumptions regarding attrition, momentary assessment completion, high-stress trigger frequency, and availability, approximately 1,225 randomized decision points are expected. Detailed power assumptions and sensitivity analyses will be prespecified in the statistical analysis plan.

Statistical Analysis Plan: The primary analysis estimates the proximal causal effect of prompt delivery on behaviour-specific urge intensity using weighted and centered least squares with robust standard errors. Binary secondary outcomes are analysed using the estimator for causal excursion effects with binary proximal outcomes. Secondary behavioural outcomes are powered for estimation rather than for confirmatory testing and are reported with confidence intervals to inform the design of a future trial.

Interpretation, Estimands, and Scope: The control condition is "no message" within the context of active momentary monitoring, rather than a neutral placebo message. The estimated causal effect therefore reflects the incremental contribution of receiving a supportive coping prompt relative to active self-monitoring alone, and does not separate the effect of the prompt's content from the effect of being notified at all. Participants are not blinded to condition, and outcomes are self-reported. The 10-minute micro-check is delivered identically across both conditions, holding proximal self-monitoring and appraisal constant across arms. These design features are inherent to the JITAI framework and are stated as part of the estimand in all reports of findings.

Safety, Privacy, and Advisory Governance: Privacy is treated as an essential component of participant safety. Notification wording is neutral and non-disclosing, and intervention content is displayed only after the participant opens the study application. Participants may decline, skip, or temporarily pause assessments at any time.

Direct identifiers are stored separately from momentary assessment data, and access is restricted to authorized study personnel. A prespecified distress-response and referral protocol operates throughout the trial.

A Community Advisory Board reviews the recruitment procedures, assessment items, support-message content, notification wording, digital safety protections, and distress-response procedures before the trial materials are finalized and locked.

Being tested
Just-in-Time Adaptive Support Message
Keywords
micro-randomized trial, just-in-time adaptive intervention, ecological momentary assessment, mHealth, digital health, minority stress, smoking, vaping, stress-attributed eating, urge, Bangladesh, gender and sexual minority, pilot optimization trial
Medical subject headings
Tobacco Use, Vaping, Emotional Eating, Stress, Psychological, Smoking, Coitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Just-in-Time Adaptive Support MessageBehavioural

    A brief, culturally adapted, in-app behavioral support message delivered on the participant's own smartphone immediately after randomization at an eligible high-stress decision point. Content is finalized and locked before the trial following a formative cultural adaptation phase and review by a Community Advisory Board. The message is matched to the participant's locked target behavior and may include grounding, urge-delay, motivational, values-based, environmental, substitute-action, social-support, or location-change strategies. It is nonjudgmental, action-oriented, designed to be read in under one minute, and requires no immediate response. At decision points randomized to the no-message option, no immediate support message is delivered.

Study groups in NCT07746492
Study groupRoleWhat they receive
Micro-randomized JITAI cohortExperimentalAll participants enter a single 24-day micro-randomized cohort. At each eligible high-stress decision point, the platform independently randomizes with probability 0.50 between two momentary options. Support prompt: The app immediately delivers one brief, culturally adapted coping-support message from a locked library. The message is matched to the participant's prespecified target behavior, can be read in under one minute, and does not disclose identity or community membership. No prompt: No immediate coping-support message is delivered. The 10-minute micro-check and 45-minute follow-up are delivered on the same schedule in both options. No existing care is withheld, and participants retain access to study contact and distress-referral information. The contrast is immediate support prompt versus no immediate support prompt. Thus, the estimated proximal effect combines receiving the message with its coping content; these components are not estimated separately.
Receives: Behavioral: Just-in-Time Adaptive Support Message

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Target-behavior momentary urge intensity

    Self-reported current urge intensity for the participant's locked target behavior, rated on an 11-point numeric rating scale from 0 to 10. For participants targeting smoking or vaping, the outcome is the urge to smoke or vape. For participants targeting stress-attributed eating, the outcome is the urge to eat in response to stress or emotional distress. Only the rating corresponding to the participant's locked target behavior contributes to the primary outcome. Scores are not combined into a within-assessment composite. A score of 0 indicates no urge at all and 10 indicates the strongest urge imaginable; higher scores indicate a worse outcome.

    Measured: At the primary follow-up delivered 45 minutes after each randomized decision point, with responses accepted through 60 minutes after randomization; assessed repeatedly throughout the 24-day assessment period.

Secondary outcomes (4)
  1. Smoking or vaping episode following randomization

    Among participants whose locked target behavior is smoking or vaping, binary self-report of whether any smoking or vaping occurred between the randomized decision point and the follow-up assessment. Coded 0 for no and 1 for yes; a higher occurrence rate indicates a worse outcome.

    Measured: From each randomized decision point through the primary follow-up delivered 45 minutes later, with responses accepted through 60 minutes after randomization; assessed repeatedly throughout the 24-day assessment period.

  2. Stress-attributed eating episode following randomization

    Among participants whose locked target behavior is stress-attributed eating, binary self-report of whether the participant ate primarily because of stress or emotional discomfort between the randomized decision point and the follow-up assessment. Eating primarily because of hunger, social context, food availability, or another non-emotional reason is not counted. Coded 0 for no and 1 for yes; a higher occurrence rate indicates a worse outcome.

    Measured: From each randomized decision point through the primary follow-up delivered 45 minutes later, with responses accepted through 60 minutes after randomization; assessed repeatedly throughout the 24-day assessment period.

  3. Momentary assessment completion rate

    Percentage of momentary assessments completed within the allowed response window, calculated overall and per participant. The denominator will include assessments delivered and available for completion and will exclude assessments automatically suppressed by the protocol because they fell within 60 minutes after a randomization. Pre-specified progression thresholds: 70 per cent or above proceed; 50 to 69 per cent proceed with protocol amendment; below 50 per cent do not proceed to a future trial without redesign.

    Measured: Across the 24-day assessment period.

  4. Participant retention through day 24

    Percentage of enrolled participants who complete the full 24-day assessment period, and the mean number of days contributed per participant. Pre-specified progression threshold: attrition of 15 per cent or less proceed; 16 to 30 per cent proceed with amendment; above 30 per cent redesign before a future trial.

    Measured: Across the 24-day assessment period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completion30 Jan 2027 (estimated)
  4. Study completion6 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Micro-Randomized Trial. All participants enter a single 24-day cohort; there are no separate permanent participant groups. Randomization occurs repeatedly within each participant, not once at enrolment, so the unit of randomization is the eligible decision point. A decision point is eligible when a completed assessment shows stress of 5 or higher (0-10 scale), the participant confirms it is safe and private to receive a message, the target behaviour has not occurred since the prior assessment, and no randomization has occurred in the preceding 90 minutes, within the allowed response window. At each eligible decision point the platform independently randomizes, with fixed probability 0.50, to immediate delivery of a brief support prompt or no prompt. These are momentary options available to every participant, not permanent groups; each participant is expected to receive both many times. Approximately 1,225 randomized decision points are expected, split evenly between options.
Masking
None (open label)
Enrolment
115 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07746492
Sponsor's protocol ID
PR-26-069
Other IDs
GR-02602
Status last verified
Jul 2026
First submitted
30 Jul 2026
Last updated
5 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be made publicly available. Participants belong to a legally and socially marginalized population in Bangladesh, and the study collects dense, repeatedly time-stamped ecological momentary assessment data within a geographically concentrated setting. These characteristics create a meaningful risk of participant re-identification even after direct identifiers are removed. Aggregate study results will be disseminated, and the study protocol and statistical analysis plan are intended to be made available through publication or an appropriate research repository, subject to institutional and journal requirements.

Publications

  • Jhe GB, Mereish EH, Gordon AR, Woulfe JM, Katz-Wise SL. Associations between anti-bisexual minority stress and body esteem and emotional eating among bi+ individuals: The protective role of individual- and community-level factors. Eat Behav. 2021 Dec;43:101575. doi: 10.1016/j.eatbeh.2021.101575. Epub 2021 Oct 14.

    PubMed 34757266
  • Santoniccolo F, Rolle L. The role of minority stress in disordered eating: a systematic review of the literature. Eat Weight Disord. 2024 Jun 8;29(1):41. doi: 10.1007/s40519-024-01671-7.

    PubMed 38850334
  • Li M, Chau K, Calabresi K, Wang Y, Wang J, Fritz J, Tseng TS. The Effect of Minority Stress Processes on Smoking for Lesbian, Gay, Bisexual, Transgender, and Queer Individuals: A Systematic Review. LGBT Health. 2024 Nov-Dec;11(8):583-605. doi: 10.1089/lgbt.2022.0323. Epub 2024 Apr 1.

    PubMed 38557209
  • Meyer IH. Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychol Bull. 2003 Sep;129(5):674-697. doi: 10.1037/0033-2909.129.5.674.

    PubMed 12956539
  • Goldstein SP, Zhang F, Klasnja P, Hoover A, Wing RR, Thomas JG. Optimizing a Just-in-Time Adaptive Intervention to Improve Dietary Adherence in Behavioral Obesity Treatment: Protocol for a Microrandomized Trial. JMIR Res Protoc. 2021 Dec 6;10(12):e33568. doi: 10.2196/33568.

    PubMed 34874892
  • Battalio SL, Conroy DE, Dempsey W, Liao P, Menictas M, Murphy S, Nahum-Shani I, Qian T, Kumar S, Spring B. Sense2Stop: A micro-randomized trial using wearable sensors to optimize a just-in-time-adaptive stress management intervention for smoking relapse prevention. Contemp Clin Trials. 2021 Oct;109:106534. doi: 10.1016/j.cct.2021.106534. Epub 2021 Aug 8.

    PubMed 34375749
  • Liu X, Deliu N, Chakraborty B. Microrandomized Trials: Developing Just-in-Time Adaptive Interventions for Better Public Health. Am J Public Health. 2023 Jan;113(1):60-69. doi: 10.2105/AJPH.2022.307150. Epub 2022 Nov 22.

    PubMed 36413704
  • Cohn ER, Qian T, Murphy SA. Sample size considerations for micro-randomized trials with binary proximal outcomes. Stat Med. 2023 Jul 20;42(16):2777-2796. doi: 10.1002/sim.9748. Epub 2023 Apr 24.

    PubMed 37094566
  • Klasnja P, Hekler EB, Shiffman S, Boruvka A, Almirall D, Tewari A, Murphy SA. Microrandomized trials: An experimental design for developing just-in-time adaptive interventions. Health Psychol. 2015 Dec;34S(0):1220-8. doi: 10.1037/hea0000305.

    PubMed 26651463
  • Nahum-Shani I, Smith SN, Spring BJ, Collins LM, Witkiewitz K, Tewari A, Murphy SA. Just-in-Time Adaptive Interventions (JITAIs) in Mobile Health: Key Components and Design Principles for Ongoing Health Behavior Support. Ann Behav Med. 2018 May 18;52(6):446-462. doi: 10.1007/s12160-016-9830-8.

    PubMed 27663578

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in